Lupin has marked the launch of its first biosimilar in Canada with its Rymti (etanercept) rival to Amgen’s Enbrel, through local marketing partner Sandoz.
Noting that Rymti “is approved for all indications of the reference product Enbrel” – including moderate to severe active rheumatoid arthritis, juvenile idiopathic arthritis, active and progressive psoriatic arthritis, severe axial spondyloarthritis, moderate to severe plaque psoriasis and chronic severe plaque psoriasis in children and adolescents
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Generics Bulletin for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?